Skip to main content
Premium Trial:

Request an Annual Quote

Automated Cell Raises $2.6M in Private Placement for Proteomics Platform

NEW YORK, Aug. 6 – Functional proteomics startup Automated Cell has raised $2.6 million in a private placement, the company said on Monday.

Automated Cell, based in Pittsburgh, Penn., said in a statement that it would use the money to expand the capacity of its platform for identifying and studying protein function, and to accelerate its drug target discovery and validation research. The company’s technology relies on cellular models of cancer and immune diseases to determine which proteins play a role in disease.

Automated Cell has an exclusive license to cell biology and robotics technology developed by scientists at the University of Pittsburgh Medical School and Carnegie Mellon University. 

In June, Automated Cell and Hybrigen said they would jointly attempt to discover and validate 12 drug targets in autoimmune diseases over 12 months.  The two companies would co-own any drug targets that result from the collaboration.

The Scan

WHO Seeks Booster Pause

According to CNN, the World Health Organization is calling for a moratorium on administering SARS-CoV-2 vaccine boosters until more of the world has received initial doses.

For Those Long Legs

With its genome sequence and subsequent RNAi analyses, researchers have examined the genes that give long legs to daddy longlegs, New Scientist says.

September Plans

The New York Times reports that the US Food and Drug Administration is aiming for early September for full approval of the Pfizer-BioNTech SARS-CoV-2 vaccine.

Nucleic Acids Research Papers on Targeting DNA Damage Response, TSMiner, VarSAn

In Nucleic Acids Research this week: genetic changes affecting DNA damage response inhibitor response, "time-series miner" approach, and more.